Stock AMGN34 AMGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Amgen Inc. Sao Paulo

Equities

AMGN34

BRAMGNBDR004

Market Closed - Sao Paulo
Other stock markets
 20:29:55 24/05/2024 BST 		5-day change 1st Jan Change
56.88 BRL +0.21% Intraday chart for Amgen Inc. -2.02% +13.87%
05-22 Sandoz: Marketing authorization for Wyost and Jubbonti in the EU CF
05-22 Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • One of the major weak points of the company is its financial situation.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 38.56 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
AMGEN INC. Stock Amgen Inc.
+13.87% 164B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 728B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 603B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 360B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+1.35% 279B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 244B
B+
NOVARTIS AG Stock Novartis AG
+8.09% 207B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.77% 205B
A+
SANOFI Stock Sanofi
-0.27% 122B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AMGN Stock
  4. AMGN34 Stock
  5. Ratings Amgen Inc.